KABAKOFF DAVID S 4

What Happened David S. Kabakoff, a director of NextCure, Inc. (NXTC), was granted 3,510 derivative shares/options on 2026-06-18. The reported acquisition price is $0.00 (code A — grant/award), so no cash was paid at grant. This is a compensation award rather than a market purchase or sale.

Key Details

• Transaction date: 2026-06-18; Form 4 filed: 2026-06-22 (timely).
• Transaction type/code: Grant/Award (A) of 3,510 derivative shares/options at $0.00.
• Total value reported at grant: $0 (acquisition price shown as $0.00 on Form 4).
• Vesting note (footnote): The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.
• Shares owned after transaction: not provided in the supplied excerpt of the filing.

Context This was a compensation grant (derivative award/option) to a director and not a purchase or sale of stock on the open market. Such grants typically vest over time and do not by themselves indicate immediate buying or selling activity; any market impact depends on future vesting, exercise, or sale.